ストックスクリーナーアプリを入手
5.08
3.79%
-0.20
前日終値:
$5.28
開ける：
$5.3
24時間の取引高:
39,470
Relative Volume:
0.05
時価総額：
$16.22M
収益：
-
当期純損益:
$-37.75M
株価収益率:
-1.5631
EPS:
-3.25
ネットキャッシュフロー:
$-30.91M
1週間 パフォーマンス:
+2.01%
1か月 パフォーマンス:
+10.20%
6か月 パフォーマンス:
+1,505%
1年 パフォーマンス:
+140.76%
1日の値動き範囲:
$5.06
$5.30
1週間の範囲:
$4.82
$5.34
52週間の値動き範囲:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
名前
Cellectar Biosciences Inc
セクター
電話
(608) 441-8120
住所
100 CAMPUS DRIVE, FLORHAM PARK, NJ
CLRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
5.08 | 15.96M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | 再開されました | Ladenburg Thalmann | Buy |
| 2020-07-01 | 開始されました | Oppenheimer | Outperform |
| 2020-01-21 | 再開されました | ROTH Capital | Buy |
| 2019-09-13 | 開始されました | ROTH Capital | Buy |
| 2016-12-21 | 開始されました | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 - Investing News Network
Cellectar Biosciences and ITM enter supply agreement for GMP-grade actinium-225 - MarketScreener
Critical Isotope Supply Deal: Cellectar Secures Ac-225 from ITM for Novel Pancreatic Cancer Treatment - Stock Titan
How to read the order book for Cellectar Biosciences Inc.Chart Signals & AI Optimized Trading Strategy Guides - Newser
How to use Fibonacci retracement on Cellectar Biosciences Inc.2025 Year in Review & Long-Term Capital Growth Ideas - Newser
Cellectar Biosciences to Participate at Oppenheimer 3rd - GlobeNewswire
Cellectar Biosciences Progresses in EMA and FDA Pathways for Iopofosine I 131 and Advances CLR 125 for Triple-Negative Breast Cancer - Quiver Quantitative
Major Breakthrough: Cellectar's Cancer Drug Iopofosine I 131 Approaches Dual EU-US Regulatory Milestones - Stock Titan
Cellectar Biosciences Inc. At Decision Level — Rebound or Resistance2025 Performance Recap & Intraday High Probability Alerts - beatles.ru
Cellectar Biosciences Inc. Shows Support at Fibonacci Level2025 Sector Review & Long-Term Capital Growth Strategies - beatles.ru
Can Cellectar Biosciences Inc. expand its profit marginsJuly 2025 Sector Moves & Free Verified High Yield Trade Plans - beatles.ru
Price Channel Expanding on Cellectar Biosciences Inc.’s ChartStop Loss & Capital Efficient Trading Techniques - beatles.ru
Traders Consider Averaging Down in Cellectar Biosciences Inc.Quarterly Portfolio Report & Accurate Intraday Trade Tips - beatles.ru
Is it time to cut losses on Cellectar Biosciences Inc.2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Building trade automation scripts for Cellectar Biosciences Inc.July 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Regression analysis insights on Cellectar Biosciences Inc. performanceCPI Data & AI Based Buy/Sell Signal Reports - Newser
Market Leaders: What drives Cellectar Biosciences Inc.’s stock price2025 Pullback Review & Accurate Buy Signal Alerts - خودرو بانک
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September - GlobeNewswire
What is Cellectar Biosciences Inc. s debt to equity ratioTrade Entry Report & Long-Term Growth Stock Strategies - خودرو بانک
Using fundamentals and technicals on Cellectar Biosciences Inc.Exit Point & Verified Short-Term Trading Plans - Newser
Chart overlay techniques for tracking Cellectar Biosciences Inc.July 2025 Volume & Real-Time Stock Price Movement Reports - Newser
Statistical indicators supporting Cellectar Biosciences Inc.’s strength2025 Trade Ideas & Weekly Top Performers Watchlists - Newser
Should you hold or exit Cellectar Biosciences Inc. nowJuly 2025 Outlook & Daily Growth Stock Investment Tips - Newser
Does Cellectar Biosciences Inc. show high probability of reboundJuly 2025 Levels & Precise Buy Zone Identification - Newser
Cellectar Biosciences, Inc. Announces Participation in Key Cancer Research Conferences and Panel Discussions This September - Quiver Quantitative
Cellectar Biosciences to Present at Multiple Medical Meetings and Industry Conferences in September. - AInvest
Breakthrough Cancer Treatment Updates: Cellectar to Share Pediatric Brain Tumor Trial Data at Key September Events - Stock Titan
Identifying reversal signals in Cellectar Biosciences Inc.2025 Technical Overview & Safe Capital Growth Tips - Newser
Using AI based signals to follow Cellectar Biosciences Inc.Treasury Yields & Stepwise Trade Signal Guides - Newser
How does Cellectar Biosciences Inc. compare to its peers2025 AllTime Highs & Reliable Volume Spike Trade Alerts - خودرو بانک
Will Cellectar Biosciences Inc. see short term momentumOptions Play & Advanced Swing Trade Entry Plans - Newser
Is Cellectar Biosciences Inc. a strong candidate for buy and hold - خودرو بانک
Real time social sentiment graph for Cellectar Biosciences Inc.2025 Institutional Moves & Community Consensus Picks - Newser
How to use a screener to detect Cellectar Biosciences Inc. breakouts2025 Volume Leaders & Intraday High Probability Setup Alerts - Newser
How moving averages guide Cellectar Biosciences Inc. trading2025 Trading Recap & Weekly Watchlist for Hot Stocks - Newser
Measuring Cellectar Biosciences Inc.’s beta against major indices2025 Market Sentiment & Free Community Supported Trade Ideas - Newser
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research - The Manila Times
Cellectar Biosciences shares fall 1.24% premarket as Oncolytics Biotech Inc. gains FDA approval for breakthrough therapies. - AInvest
Cellectar Biosciences Announces Poster Presentation at AACR Conference on Preclinical Data for Novel Cancer Treatment CLR 121225 - Quiver Quantitative
Cellectar Biosciences Presents Data on CLR 121225 in Poster Presentation at AACR Special Conference on Pancreatic Cancer Research - AInvest
Cellectar Biosciences to Present Data in Poster - GlobeNewswire
Novel Pancreatic Cancer Radio-Conjugate: Cellectar to Present Breakthrough Treatment Data at AACR Conference - Stock Titan
Analyzing drawdowns of Cellectar Biosciences Inc. with statistical toolsJuly 2025 Levels & Reliable Momentum Entry Alerts - Newser
What indicators show strength in Cellectar Biosciences Inc.2025 Performance Recap & Free Expert Approved Momentum Trade Ideas - Newser
Aug Macro: How does Cellectar Biosciences Inc. compare to its peersPortfolio Growth Summary & Weekly Chart Analysis and Guides - خودرو بانک
Cellectar Biosciences Inc. stock momentum explainedQuarterly Performance Summary & Daily Chart Pattern Signals - Newser
What is Cellectar Biosciences Inc. s revenue forecast2025 Trading Volume Trends & Fast Moving Stock Trade Plans - خودرو بانک
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionTrade Ideas & Real-Time Price Movement Reports - Newser
Is Cellectar Biosciences Inc. trending in predictive chart modelsEarnings Beat & Weekly High Conviction Trade Ideas - Newser
Cellectar Biosciences shares rise 1.87% after-hours due to FDA approval of breakthrough cancer therapies. - AInvest
Cellectar Biosciences shares fall 1.45% after-hours as Oncolytics Biotech Inc. gains regulatory momentum. - AInvest
Cellectar Biosciences Inc (CLRB) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.10%
大文字化:
|
ボリューム (24 時間):